RNA interference for improving the outcome of islet transplantation

Adv Drug Deliv Rev. 2011 Jan-Feb;63(1-2):47-68. doi: 10.1016/j.addr.2010.11.003. Epub 2010 Dec 13.

Abstract

Islet transplantation has the potential to cure type 1 diabetes. Despite recent therapeutic success, it is still not common because a large number of transplanted islets get damaged by multiple challenges including instant blood mediated inflammatory reaction, hypoxia/reperfusion injury, inflammatory cytokines, and immune rejection. RNA interference (RNAi) is a novel strategy to selectively degrade target mRNA. The use of RNAi technologies to downregulate the expression of harmful genes has the potential to improve the outcome of islet transplantation. The aim of this review is to gain a thorough understanding of biological obstacles to islet transplantation and discuss how to overcome these barriers using different RNAi technologies. This eventually will help improve islet survival and function post transplantation. Chemically synthesized small interferring RNA (siRNA), vector based short hairpin RNA (shRNA), and their critical design elements (such as sequences, promoters, and backbone) are discussed. The application of combinatorial RNAi in islet transplantation is also discussed. Last but not the least, several delivery strategies for enhanced gene silencing are discussed, including chemical modification of siRNA, complex formation, bioconjugation, and viral vectors.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems / methods*
  • Genetic Therapy / methods*
  • Humans
  • Islets of Langerhans Transplantation / methods*
  • RNA Interference*
  • RNA, Small Interfering / administration & dosage*
  • Treatment Outcome

Substances

  • RNA, Small Interfering